Quantum-Si Q3 Revenue Slides to $212K as Proteus Launch Slips to 2027
QSI sits 72% above its 52-week low of $0.69.
Summary
Quantum-Si posted Q3 2026 revenue of $212,000, down from $552,000 a year earlier, as customers hold off on Platinum purchases ahead of the Proteus launch now targeted for Q2 2027. The company cut full-year adjusted operating expense guidance to $87.0 million or less from $98.0 million and total cash usage to $87.0 million or less from $93.0 million, reflecting the 20% workforce reduction completed in the quarter. Net loss narrowed to $22.3 million from $35.7 million, and cash plus investments stood at $149.4 million at September 30, which management says funds operations into Q4 2028. Management also launched a Proteus pre-order program and said it has largely fixed the instrument variability issues flagged earlier in development, with the 20th amino acid detection expected by year-end. The revenue base is now near zero, so the story is entirely about whether Proteus ships on time and whether the $149.4 million lasts; watch for the promised updates on system performance and commercial readiness through the first half of 2027.
At the time of this announcement, QSI was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $256.1M. The 52-week trading range was $0.69 to $1.89. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.